NV-101: Empower your ALS Initiatives

Accelerate your advancements towards ALS treatment. Our NV-101 gene therapy AAV vector targets cells in the brain and spinal cord to make a protective agent (GDNF) to shield motor neurons in ALS patients. NV-101 utilizes our initial AAV candidate (AV-01) that exhibits superior efficacy and diffusion, compared to other AAVs delivering GDNF.

NV-102: Advance targeting for Huntington’s and Parkinson’s protocols

Attain both greater neuroprotective and anti-inflammatory attributes for treatments related to Huntington’s Disease and Parkinson’s Disease. NV-102 is designed to pair with other vectors to help modulate inflammation (by targeting endogenous chitinases and chitinase-like proteins). Because Huntington’s presents the same target structure as Parkinson’s, NV-102 can support feasibility, safety, and efficacy data in a clinical setting.